Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duvortuxizumab - MacroGenics

Next Previous
Drug Profile

Duvortuxizumab - MacroGenics

Alternative Names: Anti-CD3/CD19 monoclonal-antibody; CD3-CD19 DART protein; CD3xCD19 DART molecule; JNJ-64052781; MGD 011

Latest Information Update: 30 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Developer Janssen Biotech; MacroGenics
  • Class Bispecific antibodies
  • Mechanism of Action CD19 antigen modulators; CD3 antigen modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma

Most Recent Events

  • 31 Aug 2017 Discontinued - Phase-I for Haematological malignancies (Second-line therapy or greater) in France, Israel, Spain, Belgium (IV)
  • 31 Aug 2017 Janssen terminates a phase I trial in Haematological malignancies (Second-line therapy or greater) in USA, Spain, Israel, France, Belgium due to treatment-related neurotoxicity (IV) (NCT02454270) (EudraCT2015-000485-63)
  • 31 Aug 2017 Janssen Biotech terminates its licence for duvortuxizumab

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top